{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidrhj3nbmjf2shynztoogadv4mh445vdlzbrrkw656da3noahm52y",
    "uri": "at://did:plc:73txmnzc4imhrv5q7azno3up/app.bsky.feed.post/3megxsrdglmv2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreie7zenn3cprtim4yopid4zj7ixelwcf3pduxpguzjx7pi6mrdighm"
    },
    "mimeType": "image/jpeg",
    "size": 39678
  },
  "path": "/news/science/165786-russia-allergy-vaccine-temporary-registration-2026/",
  "publishedAt": "2026-02-09T16:33:00.000Z",
  "site": "https://english.pravda.ru",
  "tags": [
    "Science"
  ],
  "textContent": "Russia is preparing to grant temporary registration to a new allergy vaccine during the second quarter of 2026, signaling a major step forward in the country's efforts to develop advanced immunological treatments.\nThe announcement was made by Veronika Skvortsova, head of the Federal Medical-Biological Agency, during a scientific press conference focused on key achievements in life sciences and the implementation of Russia's national research strategy.\nTemporary Approval Expected in Mid-2026\n\n\n\n\"We expect temporary registration in the second quarter of this year. At the same time, patient recruitment for the third phase of clinical trials is nearing completion. After the 2026 pollen season, we hope to apply for permanent registration of this vaccine,” Skvortsova said.",
  "title": "Russia Moves Toward Launch of First Recombinant Allergy Vaccine"
}